Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inhibrx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INBX
Nasdaq
8731
https://inhibrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inhibrx Inc
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
- Feb 28th, 2024 3:25 pm
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Feb 28th, 2024 2:15 pm
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
- Jan 25th, 2024 2:26 pm
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
- Jan 24th, 2024 3:42 pm
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
- Jan 24th, 2024 10:58 am
Inhibrx Soared 176% Over Two Months — Now, Sanofi Is Buying It
- Jan 23rd, 2024 9:02 pm
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
- Jan 23rd, 2024 7:30 pm
Sanofi to buy Inhibrx in deal worth up to $2.2B
- Jan 23rd, 2024 11:02 am
France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal
- Jan 23rd, 2024 6:32 am
UPDATE 3-France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal
- Jan 23rd, 2024 6:29 am
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
- Jan 23rd, 2024 6:00 am
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Nov 9th, 2023 9:00 pm
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
- Nov 2nd, 2023 1:15 pm
Inhibrx Announces Participation in Upcoming Scientific Conferences
- Oct 18th, 2023 8:00 pm
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
- Sep 19th, 2023 8:00 pm
12 Best High Risk High Reward Stocks To Buy Now
- Sep 1st, 2023 2:16 am
Inhibrx Announces $200 Million Private Placement Financing
- Aug 29th, 2023 1:00 pm
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 7th, 2023 8:00 pm
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
- May 30th, 2023 1:00 pm
Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates
- May 8th, 2023 10:05 pm
Scroll